{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:01:21Z","timestamp":1790002881710,"version":"4.0.1"},"reference-count":35,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) may alleviate suppression of antitumor immune responses by overcoming redundant immunosuppressive pathways. This study evaluated the combination of KHK2455, a novel and selective, long-lasting, and potent oral IDO1 inhibitor, with avelumab, a PD-L1 inhibitor, in adults with locally advanced or metastatic urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, open-label Phase 1 study evaluated the safety and tolerability of oral daily KHK2455 (30, 100, and 200 mg) plus intravenous avelumab (800 mg biweekly), the safety of KHK2455 200 mg monotherapy, KHK2455 and avelumab antitumor activity, avelumab antidrug antibodies, and combination therapy pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>16 subjects were enrolled (n=4, 4, and 8 in the 30, 100 and 200 mg cohorts, respectively). No dose-dependency was observed for KHK2455-only related treatment-emergent adverse events (TEAEs). No TEAEs were considered related to KHK2455 or avelumab. Four subjects had fatal TEAEs considered not related to treatment.<\/jats:p>\n                    <jats:p>One subject in the KHK2455 30 mg cohort achieved a complete response (CR) and one in the KHK2455 200 mg cohort achieved a partial response (PR), both with avelumab.<\/jats:p>\n                    <jats:p>PD-L1 expression was evaluated in the 13 available baseline tumor biopsy samples. All biopsies expressed PD-L1 in at least one compartment; 31% (4\/13) were positive on tumor cells and 69.2% (9\/13) were positive on tumor-associated immune cells. Over half (53.8%, 7\/13) expressed PD-L1 at high levels and within the disease control group consisting of CR (n=1), PR (n=1) and stable disease (n=5), 57.1% (4\/7) were PD-L1 high. Baseline expression profiles showed significantly higher immune activation in the subject with CR compared with the subject with PR and those with progressive disease. The subject with CR had the highest baseline Tumor Inflammation Signature (TIS) score (9.06) compared with 4.8 in the subject with PR and lower TIS score values in subjects with progressive disease. Changes in gene expression were observed, including upregulation of CXCL12, CCND2, and MMRN2, and downregulation of HLA-DRB5, CRABP2, and VEGFA in responders versus progressive disease comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The favorable safety profile and preliminary efficacy results of KHK2455 in combination with avelumab, along with the translational biomarker findings, warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015178","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:10:32Z","timestamp":1789999832000},"page":"e015178","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02752074","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03915405","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02994953","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03915405","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":false,"given":"Yousef","family":"Zakharia","sequence":"first","affiliation":[{"name":"University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA"},{"name":"Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Doger","family":"de Sp\u00e9ville","sequence":"additional","affiliation":[{"name":"START Center for Cancer Research, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Morales-Barrera","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-6388","authenticated-orcid":false,"given":"Irene","family":"Moreno","sequence":"additional","affiliation":[{"name":"Start Madrid- CIOCC, Centro Integral Oncologico Clara Campal, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin Department of Medicine, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Peguero","sequence":"additional","affiliation":[{"name":"Oncology Consultants PA, P1 Pratia Oncology, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Rao","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2271-9363","authenticated-orcid":false,"given":"Lisa H","family":"Shiue","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Kanda","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Arora","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Vuppugalla","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital del Mar Medical Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092107101178000_14.9.e015178.1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010131","article-title":"Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092107101178000_14.9.e015178.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-11213-6","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303\/KEYNOTE-698 study","volume":"23","author":"Cicin","year":"2024","journal-title":"BMC Cancer"},{"key":"2026092107101178000_14.9.e015178.3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00428-024-03795-8","article-title":"Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments","volume":"484","author":"R\u00fcschoff","year":"2024","journal-title":"Virchows Arch"},{"key":"2026092107101178000_14.9.e015178.4","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10147-025-02873-4","article-title":"First-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making","volume":"30","author":"Nagumo","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2026092107101178000_14.9.e015178.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8"},{"key":"2026092107101178000_14.9.e015178.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-01847-4","article-title":"What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past","volume":"40","author":"Yao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026092107101178000_14.9.e015178.7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01080-8"},{"key":"2026092107101178000_14.9.e015178.8","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35939","article-title":"First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors","volume":"131","author":"Yap","year":"2025","journal-title":"Cancer"},{"key":"2026092107101178000_14.9.e015178.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"2026092107101178000_14.9.e015178.10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5858\/arpa.2017-0555-OA","article-title":"Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma","volume":"143","author":"Zajac","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"2026092107101178000_14.9.e015178.11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026092107101178000_14.9.e015178.12","doi-asserted-by":"publisher","DOI":"10.1593\/neo.131568"},{"key":"2026092107101178000_14.9.e015178.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"2026092107101178000_14.9.e015178.14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011"},{"key":"2026092107101178000_14.9.e015178.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005813","article-title":"First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma","volume":"11","author":"Strauss","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092107101178000_14.9.e015178.16","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-0395","article-title":"Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma","volume":"30","author":"D\u2019Angelo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092107101178000_14.9.e015178.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06276-x","article-title":"IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"2026092107101178000_14.9.e015178.18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/07391102.2024.2332509","article-title":"Identification of putative Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) dual inhibitors for triple-negative breast cancer therapy","volume":"44","author":"Paranthaman","year":"2026","journal-title":"J Biomol Struct Dyn"},{"key":"2026092107101178000_14.9.e015178.19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s12951-024-02936-0","article-title":"HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability","volume":"22","author":"Liang","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"2026092107101178000_14.9.e015178.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002057","article-title":"Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma","volume":"9","author":"Zakharia","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026092107101178000_14.9.e015178.21","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03925-w","article-title":"IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization","volume":"74","author":"Guangzhao","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026092107101178000_14.9.e015178.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0702-0"},{"key":"2026092107101178000_14.9.e015178.23","doi-asserted-by":"crossref","unstructured":"Smith M , Newton R , Owens S , et al . 28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies. J Immunotherapy Cancer 2020;8. doi:10.1136\/jitc-2020-SITC2020.0028","DOI":"10.1136\/jitc-2020-SITC2020.0028"},{"key":"2026092107101178000_14.9.e015178.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2285"},{"key":"2026092107101178000_14.9.e015178.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31178"},{"key":"2026092107101178000_14.9.e015178.26","article-title":"Cancer Immunotherapy by Targeting IDO1\/TDO and Their Downstream Effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front Immunol"},{"key":"2026092107101178000_14.9.e015178.27","first-page":"1632446","article-title":"IDO1\/TDO2 expression profiling in cancer: implications for biomarker-driven immunotherapy","volume":"16","author":"Varadi","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026092107101178000_14.9.e015178.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026092107101178000_14.9.e015178.29","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-21"},{"key":"2026092107101178000_14.9.e015178.30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noad174","article-title":"Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial","volume":"26","author":"Johnson","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026092107101178000_14.9.e015178.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886225","article-title":"Impact of IDO1 and IDO2 on the B Cell Immune Response","volume":"13","author":"Merlo","year":"2022","journal-title":"Front Immunol"},{"key":"2026092107101178000_14.9.e015178.32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix550"},{"key":"2026092107101178000_14.9.e015178.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00388","article-title":"IDO and Kynurenine Metabolites in Peripheral and CNS Disorders","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"2026092107101178000_14.9.e015178.34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247531","article-title":"Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection","volume":"12","author":"Wi\u015bnicki","year":"2023","journal-title":"J Clin Med"},{"key":"2026092107101178000_14.9.e015178.35","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk4898","article-title":"A metabolic dependency of EBV can be targeted to hinder B cell transformation","volume":"385","author":"M\u00fcller-Durovic","year":"2024","journal-title":"Science"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:10:37Z","timestamp":1789999837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015178"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015178","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}